In an open-label observational trial at Primary Children’s hospital, 25 children and teens with treatment-resistant epilepsy who apply to be part of a new drug trial will, will receive Epidiolex, a liquid, purified form of cannabidiol (CBD), a non-psychoactive chemical in marijuana.

The primary goal will be to test the tolerability of Epidiolex and the optimal dose of CBD, a chemical shown to have powerful anti-seizure properties in children who have tried whole-plant marijuana extracts.

Parent activists who pushed for Charlee’s Law — which frees Utahns with epilepsy to import whole-plant CBD extracts from states where medical marijuana is legal — have long hoped Primary Children’s would study Epidiolex.

But the timing of the study poses a challenge for families who are on a waiting list for a highly sought CBD oil made by Colorado Springs growers at the Realm of Caring Foundation.

Those families will be eligible to apply for a Utah “hemp supplement” registration card starting July 8. But taking the oil could exclude them from participating in Primary Children’s study, which has an unknown start date.

“It’s a decision point for families, to do this study or try a whole plant extract,” acknowledged Clark.

Read Full Story On: sltrib


Join the conversation! 1 Comment

  1. […] research of hemp extract treatment will be conducted at the University of Utah and Primary Children’s […]

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

About Canna Magazine

This is the “wpengine” admin user that our staff uses to gain access to your admin area to provide support and troubleshooting. It can only be accessed by a button in our secure log that auto generates a password and dumps that password after the staff member has logged in. We have taken extreme measures to ensure that our own user is not going to be misused to harm any of our clients sites.

Category

Medical, Research

Tags

, , , , , ,